| DRUG REVIEW |
|
| Year : 2022 | Volume
: 24
| Issue : 2 | Page : 63-70 |
|
|
Beta-lactam beta-lactamase inhibitors
Sangeeta Joshi
Department Microbiology, Manipal Hospital, New Delhi, India
Correspondence Address:
Sangeeta Joshi
94, Dhaula Kuan Part 1, Delhi Cantt. New Delhi - 110 010
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jacm.jacm_21_22
|
|
|
Four new β lactam-β lactamase inhibitor (BL-BLI) combinations, namely ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and imipenem-cilastatin-relebactam are currently approved by the Food and Drug Administration for complicated urinary tract infections (cUTIs), complicated intra-abdominal infections (cIAIs) and two of them for hospital-acquired pneumonia/ventilator-associated pneumonia. The clinical trials of these antibiotics have shown them to be non-inferior to comparator antibiotics. These antibiotics have action against extended-spectrum beta-lactamase enterobacterales and Klebsiella pneumoniae carbapenemase producers. Some have action against OXA-48 producing Gram-negative bacilli. However, all the above BL-BLI antibiotics have no action against metallo-β lactamase-producing organisms. These are currently being used for the treatment of cUTI and cIAI caused by multidrug-resistant (MDR) Enterobacterales and MDR Pseudomonas aeruginosa.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
